Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cypralis, Gilead Sciences Amend Cyprolides Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Cypralis, Gilead Sciences Amend Cyprolides Alliance

Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology. This follows a multi-year drug discovery collaboration between Selcia Ltd. and Gilead under which Selcia provided integrated drug discovery services to support Gilead’s liver disease research programs. The research phase ended in 2013 and Selcia’s rights have since been transferred to Cypralis.
 
Under the research collaboration, Selcia and Gilead generated four jointly owned patents and two preclinical candidates. 
 
Simon Kerr, chief executive officer, Cypralis, said, “Cyprolides are a new class of fully synthetic cyclophilin inhibitors that are potent inhibitors of cyclophilin D and protect against opening of the mitochondrial permeability transition pore. This property leads to protection of cells and tissues associated with several diseases such as neurodegeneration, fibrosis and other mitochondrially-mediated diseases. By focusing upon acute and chronic degenerative diseases, we aim to exploit the properties of this new class of compound in areas outside of oncology and virology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics